The ADVENT trial of Boston Scientific’s Farapulse pulsed field ablation (PFA) system met its primary and safety efficacy endpoints.
ADVENT is the first randomized trial to compare PFA to standard-of-care ablation with a radiofrequency or cryoablation ablation catheter in patients with drug-resistant paroxysmal atrial fibrillation. (Also see "JPM...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?